#### Balloon and Mesh Catheter Ablation of Pulmonary Veins

**ISHNE 2009** 

Atul Verma, MD FRCPC Cardiology/Electrophysiology Heart Rhythm Program, Division of Cardiology Southlake Regional Health Centre Newmarket, Ontario, Canada

September, 2009



## Disclosures

- Moderate Support (honoraria, speaking bureau, research)
  - St Jude Medical International
  - Medtronic Canada
  - Biosense Webster
- Advisory Board
  - St Jude Medical International
  - Biosense Webster



# Objectives

- Better understand where we are in the application of balloon and mesh technologies for ablation of pulmonary veins
- Assess the benefits and limitations of both approaches
- To characterize the type of patient where this technology will be best applied



- 50 year old male
- Past medical history appendectomy, hypertension
- 5 years of symptomatic paroxysmal atrial fibrillation
- Episodes last 3-4 hours and occur every week
- Failed propafenone and sotalol
- LA size is 43 mm in PLAX view
- You book him for AF ablation



- Which of the following techniques would you use (assuming all were available to you)?
- A = point by point catheter-based PVI
- B = balloon-based cryoablation PVI
- C = mesh-based ablater PVI
- D = remote navigation based PVI



- 50 year old male
- Past medical history hypertension, hyperlipidemia, sleep apnea with CPAP
- 8 years of symptomatic paroxysmal atrial fibrillation which has become persistent
- Feels much better when cardioverted, but only lasts 2-3 weeks
- Failed sotalol, flecainide, and now dofetilide
- LA size is 48 mm in PLAX view
- You book her for AF ablation



- Which of the following techniques would you use (assuming all were available to you)?
- A = point by point catheter-based ablation
- B = balloon-based cryoablation
- C = mesh-based ablater
- D = remote navigation based ablation



#### **Balloon-Based Ablation**





- Investigational Device Exemption (IDE) Study ongoing and is not available for sale in the United States.
- The information provided does not constitute any safety and effectiveness claims.



 The Arctic Front Cardiac CryoAblation Catheter is intended for the treatment of patients suffering from paroxysmal atrial fibrillation (PAF). Adjunct devices (Freezor MAX) can be used with Arctic Front in the treatment of PAF.









23mm

28mm













#### Lower Incidence of Thrombus Formation with Cryoenergy Vs Radiofrequency Catheter Ablation RF CRYO



#### Effect on the Connective Tissue Matrix and Thrombogenicity



Khairy et al. Circulation. 2003; 107:2045-50





## **Complete Occlusion is Key**





## Occlusion is Key






- Contact with entire PV ostium
- Blood flow halted = better cooling
- Circumferential lesion with single application



## Leak = Incomplete Lesions





#### **Case Study: Cryoballoon**




## **Optimizing Occlusion**



Incomplete LSPV occlusion with leak of contrast into the atrium (Guide wire in inferior branch)



## **ICE** Monitoring for Leak




## **Optimizing Occlusion**



Incomplete LSPV occlusion with leak of contrast into the atrium (Guide wire in superior branch)




#### **Optimizing Occlusion**



Complete LIPV occlusion with no leak of contrast into the atrium




#### **Cryoablation and Right Pulmonary Veins**



Complete RIPV occlusion with no leak of contrast into the atrium and pacing the phrenic nerve with a quadripolar catheter Courtesy Marc Dubuc, MD

## Inferior PVs can be a Challenge



## **Clinical Results - Cryoballoon**


	Number of pts	Type of AF	Acute Success	F/U (days)	Outcomes	Comments/ Complicat'n
Chun, Kuck et al, 2009 (28 mm)	27	100% parox, lone AF	98% PVs isolated except 2 RIPVs	271	70% cure (TTM)	3 PNPs – recovered 0,28,384 d
Van Belle et al, 2008	139	100% parox, lone AF	100% PVs w/ balloon & cath	457	59% cure (1,2 proc)	4 PNPs – recov 6 mo
Malmborg et al, 2008	40	80% parox, 18% parox/persist	91% had PVI w/ ball & cath	270	45% cure off drug, 53% on	2 PNPs, 2 dysphagia
Neumann et al, 2008	346	85% parox, 15% persist	97% had PVI w/ ball & cath	Median 365 (76% >6mo)	74% parox, 42% persist, some loss f/u (7d Holter)	24 PNPs, mostly w/ 23 mm, resolve <1y
Klein et al, 2008	21	100% parox	95% of PVs isolated	172	86% (Holter)	3 PNPs

# **Clinical Results**

- Predominantly paroxysmal, lone AF population
- Most of these done by skilled operators
- Success rates of traditional catheter ablation 75%-90% after 1-2 procedures in this population
- Success rates seem a bit lower
- Follow-up duration is limited
- Risk of PNP but most resolve within 6-12 mo
- Faster, shorter procedure




## Level of Isolation – Ostial or Antral?





Reddy et al, Heart Rhythm 2008

## Level of Isolation – Ostial or Antral?




*Conclusions* In cryoballoon PVI, the majority of the veins undergo antral isolation. Veins with a diameter larger than the balloon, are isolated ostially. In individual cases, the left atrial activation sequence appears to be altered after ablation.


Used larger 28 mm balloon diameter.

Van Belle et al, J Interv Card Electrophysiol 2009



## Cardiofocus – Laser Balloon





Diode laser system Endoscope viewer - reusable

From Reddy et al, Heart Rhythm 2008



# Cardiofocus – Laser Balloon


- Not much published data
- Abstract presented at AHA 2007
- 30 pts with paroxysmal AF
- Acute isolation achieved in 91% of PVs
- 70% AF-free 6 mo, 67% AF-free 12 mo
- 2 on antiarrhythmics (60% success off drugs)
- 3 adverse events (not specified)


Circulation, Supplement II, Vol 116, No 16 October 16, 2007, 2440 pp II-536



## **HIFU Balloon**







High Frequency Focused Ultrasound
Reflected off a saline gas interface
Forward focused in a ring pattern



# **HIFU Balloon**


- Nakagawa et al, JCE 2007 (n=27)
  - 87% acute PV isolation, 59% AF-free at 12 months
  - 1 phrenic nerve palsy
- Schmidt et al, Heart Rhythm 2007 (n=15)
  - 89% acute PV isolation, 58% AF-free at 12 months
  - 2 permanent phrenic nerve palsies
- US Pivotal Trial (n=240)
  - Started Jan 2007, 25 enrolling centers
  - Approx 69 patients enrolled study halted May 2008 to investigate serious adverse events



#### **Mesh Ablator**




#### Bard HD – Mesh Ablator Catheter






## Bard HD – Mesh Ablator Catheter


- 36 pole design allows for detailed PV signal mapping
- Delivers RF energy to multiple poles simultaneously – temperature controlled
- Pulsed RF energy delivery – contiguous lesions, prevents overheating and char
- Does not occlude blood flow – mesh design









#### Bard HD – Mesh Ablator






#### From Mansour et al, Heart Rhythm 2008

# Positioning the Mesh




Use fluoroscopy with PV angiography, signals (look for atrial and PV signals.



From DeFillipo et al, JCE 2009

Can also use ICE or electroanatomical mapping system.

From Mansour et al, HR 2008



Delivered unipolar, pulsed in 5 ms pulses and delivered in alternating fashion to half of the electrodes followed by the other half. Deliver max 80-100 W to a target temp of 55-60 C. Look at 4 thermocouples – if temp is target in 3 of 4, continue for 300 sec. If not, adjust position.

## Clinical Results – Mesh Ablator

	Number of pts	Type of AF	Acute Success	F/U (days)	Outcomes	Comments/ Complicat'n
Mansour et al, 2008	20	100% parox, Ione AF	63% of PVs isolated, rest req usual abl'n	0	No longer term outcome	No complic'ns
DeFillipo et al, 2009	17	10 parox, 7 persistent	All PVs isolated, but only 47% RIPV	330	64% in sinus on drugs	No complic'ns
Meissner et al, 2009	26	14 parox, 12 persistent	94% of PVs isolated	90	65% in sinus by symptoms	No complic'ns
Steinwender et al, 2009	26	100% parox, Ione AF	97% of PVs isolated	3-6 mos	57-60% in sinus	1 tamponade

- •On average, about 9-12 min RF required per PV.
- •Average procedure duration is about 3-4 hours.
- •Average fluoro time was about 31-42 mins.

## Mesh Ablator

- Success rates not as high as balloon technology
- Procedural and fluoro times are longer
- Very small number of patients studied
- Larger trials are required



# Summary

- Balloon and mesh based technologies are promising avenues
- At this point, balloon technologies are further ahead in success and procedural efficiency
- Results not quite as good as traditional ablation and mostly limited to pure paroxysmals
- Further clinical evaluation/trials required to assess where these will "fit" in therapeutic armamentarium

